Trial Profile
An Open-label, Long-term Extended Access Protocol for Rapastinel as Adjunctive or Monotherapy Treatment in Patients With Major Depressive Disorder
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Jul 2020
Price :
$35
*
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Allergan
- 17 Jul 2019 Status changed from recruiting to discontinued.
- 19 Sep 2018 New trial record